• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清去γ-羧基凝血酶原半衰期是肝细胞癌肝切除术后生存和复发的预后指标。

The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma.

作者信息

Okamura Yukiyasu, Sugiura Teiichi, Ito Takaaki, Yamamoto Yusuke, Ashida Ryo, Uesaka Katsuhiko

机构信息

Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

出版信息

Ann Surg Oncol. 2016 Dec;23(Suppl 5):921-928. doi: 10.1245/s10434-016-5570-z. Epub 2016 Sep 14.

DOI:10.1245/s10434-016-5570-z
PMID:27638677
Abstract

BACKGROUND

Des-γ-carboxy prothrombin (DCP) is a representative tumor marker of hepatocellular carcinoma (HCC), and its values are occasionally very high in HCC cases. The current study aimed to clarify the postoperative half-life of DCP as a prognostic factor.

METHODS

This retrospective study enrolled 177 patients who had undergone liver resection as an initial treatment for HCC. Three DCP half-life groups were defined as follows: within the normal range, half-life shorter than 4 days, and half-life of 4 days or longer. The overall and recurrence-free survival rates were estimated and compared among the three groups.

RESULTS

There were 140 patients in the group with a DCP half-life in the normal range, 19 patients in the group with a DCP half-life shorter 4 days, and 18 patients in the group with a DCP half-life of 4 days or longer. A multivariate analysis showed that only a postoperative DCP half-life of 4 days or longer was an independent prognostic risk factor for overall and recurrence-free survival (respective hazard ratios of 2.92 and 4.19; P < 0.001). The group with a preoperative DCP value lower than 1400 mAU/mL, the median value of DCP in the current study, included no patients from the group with a half-life shorter than 4 days. The overall and recurrence-free survival rates in the group with a half-life of 4 days or longer were significantly poorer (P < 0.001) than in the group that had a half-life shorter than 4 days (P = 0.002) with a preoperative DCP status of 1400 mAU/mL or more.

CONCLUSIONS

The current study showed for the first time that a prolonged half-life of DCP is an independent prognostic risk factor for survival and recurrence after liver resection with curative intent.

摘要

背景

去γ-羧基凝血酶原(DCP)是肝细胞癌(HCC)的代表性肿瘤标志物,其值在HCC病例中偶尔会非常高。本研究旨在阐明DCP作为预后因素的术后半衰期。

方法

本回顾性研究纳入了177例行肝切除术作为HCC初始治疗的患者。三个DCP半衰期组定义如下:正常范围内、半衰期短于4天、半衰期为4天或更长。估计并比较三组的总生存率和无复发生存率。

结果

DCP半衰期在正常范围内的组有140例患者,DCP半衰期短于4天的组有19例患者,DCP半衰期为4天或更长的组有18例患者。多因素分析显示,仅术后DCP半衰期为4天或更长是总生存和无复发生存的独立预后危险因素(各自的风险比为2.92和4.19;P<0.001)。术前DCP值低于本研究中DCP中位数1400 mAU/mL的组中,没有半衰期短于4天组的患者。半衰期为4天或更长的组的总生存率和无复发生存率显著低于(P<0.001)术前DCP状态为1400 mAU/mL或更高且半衰期短于4天的组(P=0.002)。

结论

本研究首次表明,DCP半衰期延长是根治性肝切除术后生存和复发的独立预后危险因素。

相似文献

1
The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma.血清去γ-羧基凝血酶原半衰期是肝细胞癌肝切除术后生存和复发的预后指标。
Ann Surg Oncol. 2016 Dec;23(Suppl 5):921-928. doi: 10.1245/s10434-016-5570-z. Epub 2016 Sep 14.
2
Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.术前甲胎蛋白和脱γ-羧基凝血酶原在肝细胞癌患者中的预后作用
World J Gastroenterol. 2015 Apr 28;21(16):4933-45. doi: 10.3748/wjg.v21.i16.4933.
3
Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.消融后去γ-羧基凝血酶原水平可预测乙型肝炎相关肝细胞癌的预后。
Liver Int. 2016 Apr;36(4):580-7. doi: 10.1111/liv.12991. Epub 2015 Nov 18.
4
Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.肿瘤标志物在不同血管侵犯模式的复发性肝细胞癌患者中的预测价值。
Hepatobiliary Pancreat Dis Int. 2016 Aug;15(4):371-7. doi: 10.1016/s1499-3872(16)60095-4.
5
Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.甲胎蛋白和异常凝血酶原阳性状态:复发性肝细胞癌的重要预后因素。
World J Surg. 2004 Jul;28(7):702-7. doi: 10.1007/s00268-004-7205-y. Epub 2004 Jun 8.
6
Clinical Significance of Preoperative Hepatocellular Carcinoma With High Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.术前甲胎蛋白凝集素反应性分数高但甲胎蛋白水平低的肝细胞癌的临床意义
Anticancer Res. 2019 Feb;39(2):883-889. doi: 10.21873/anticanres.13189.
7
Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.术前甲胎蛋白和脱γ-羧基凝血酶原联合检测预测乙型肝炎相关肝细胞癌患者根治性切除术后复发。
Int J Cancer. 2012 Nov 15;131(10):2332-41. doi: 10.1002/ijc.27507. Epub 2012 Mar 28.
8
Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.甲胎蛋白和去γ-羧基凝血酶原在接受肝切除术的肝细胞癌患者中的意义。
Ann Surg Oncol. 2009 Oct;16(10):2795-804. doi: 10.1245/s10434-009-0618-y. Epub 2009 Aug 11.
9
Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.去γ-羧基凝血酶原在活体肝移植治疗复发性肝细胞癌中的预后影响
Transplant Proc. 2015 Apr;47(3):703-4. doi: 10.1016/j.transproceed.2014.09.178. Epub 2015 Mar 27.
10
Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma.去γ-羧基凝血酶原(DCP)比值,一种通过单克隆抗体MU-3和19B7测量的新参数,作为肝细胞癌的一种新的预后指标。
Liver Int. 2003 Feb;23(1):38-44. doi: 10.1034/j.1600-0676.2003.01777.x.

引用本文的文献

1
A Large-Scale Retrospective Study of Serum Des-Gamma-Carboxy Prothrombin as a Diagnostic Marker of HCC: Effect of Liver Function on Specificity.一项关于血清去γ-羧基凝血酶原作为肝癌诊断标志物的大规模回顾性研究:肝功能对特异性的影响。
J Clin Lab Anal. 2025 May;39(10):e70025. doi: 10.1002/jcla.70025. Epub 2025 Apr 14.
2
Current status and new directions for hepatocellular carcinoma diagnosis.肝细胞癌诊断的现状与新方向
Liver Res. 2024 Dec 5;8(4):218-236. doi: 10.1016/j.livres.2024.12.001. eCollection 2024 Dec.
3
Combined PIVKA II and Vimentin-Guided EMT Tracking in Pancreatic Adenocarcinoma Combined Biomarker-Guided EMT Tracking in PDAC.
联合PIVKA II和波形蛋白引导的胰腺癌上皮-间质转化追踪 胰腺癌联合生物标志物引导的上皮-间质转化追踪
Cancers (Basel). 2024 Jun 27;16(13):2362. doi: 10.3390/cancers16132362.
4
Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter.直径超过 3.0 厘米的肝细胞癌射频消融治疗的长期疗效和适应证。
Sci Rep. 2023 Sep 28;13(1):16286. doi: 10.1038/s41598-023-43516-w.
5
Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.三种生物标志物的纵向监测预测肝癌根治性切除术后复发。
Eur J Gastroenterol Hepatol. 2023 Oct 1;35(10):1178-1185. doi: 10.1097/MEG.0000000000002610. Epub 2023 Jul 11.
6
Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation.去γ-羧基凝血酶原的短半衰期是早期预测接受射频消融治疗的肝细胞癌预后的优越因素。
Diagnostics (Basel). 2023 Feb 12;13(4):696. doi: 10.3390/diagnostics13040696.
7
Hepatic and Vascular Vitamin K Status in Patients with High Cardiovascular Risk.高心血管风险患者的肝脏和血管维生素 K 状况。
Nutrients. 2021 Oct 1;13(10):3490. doi: 10.3390/nu13103490.
8
PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.异常凝血酶原 II:一种用于诊断和监测胰腺腺癌患者的生物标志物。
PLoS One. 2021 May 20;16(5):e0251656. doi: 10.1371/journal.pone.0251656. eCollection 2021.
9
Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402.去γ-羧基凝血酶原影响边缘肝功能 HCC 患者的生存和根治性治疗:ACROS1402。
J Cancer Res Clin Oncol. 2020 Nov;146(11):2949-2956. doi: 10.1007/s00432-020-03270-2. Epub 2020 May 27.